Hangzhou Tigermed Consulting Co., Ltd.
Tigermed is a China-based contract research organization that provides solutions such as regulatory affairs, clinical operations and biometrics for the healthcare sector.
Business Model: Consulting
Revenue: $710.5M
Employees: 5,001-10,000
Rankings
Industries / Tags:
Detailed Hangzhou Tigermed Consulting Co., Ltd. Information
Geographic Data
Address: No.3760 Nanhuan Road
City: Hangzhou
State: zhejiang province
Zip: 310053
Country: CN
Financial Info
Stage:
series unknown
Raised Last:
$2M
Raised Total:$8M
Social
Metrics
4,182,236Website Global Rank
2,656Website Monthly Traffic
Twitter Followers
Description
Tigermed is a China-based contract research organization that provides solutions such as regulatory affairs, clinical operations and biometrics for the healthcare sector.
Contact Phone:
Contact Email:
Hangzhou Tigermed Consulting Co., Ltd. went public on 8/7/2020 on the Shenzhen Stock Exchange
Listed Exchange:
Shenzhen Stock Exchange
IPO Date:
8/7/2020
Ticker Symbol:
3347
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2020 | Adlai Nortye | Series C | 0 |
| 10/2022 | Hipower | Series B | - |
| 9/2017 | MED.CIRCLE | Angel Round | 450.8k |
| 2/2020 | CANbridge Pharmaceuticals | Series D | 98M |
| 5/2015 | Yijiayi | Series A | 2.4M |
| 10/2020 | 3D Medicines | Venture Round | 0 |
| 1/2018 | Collietech | Corporate Round | - |
| 3/2021 | Gmax Biopharm | Series C | 78M |
| 6/2020 | Asieris Pharmaceuticals | Series C | 41M |
| 7/2019 | Yaxincheng | Venture Round | 11.9M |
| 11/2021 | Jisi Yingda | Series B | - |
| 12/2015 | NovaSignal | Series A | 10M |
| 9/2021 | CytoLynx Therapeutics | Funding Round | 0 |
| 5/2017 | Yaxincheng | Angel Round | 434.3k |
| 4/2022 | LTZ Therapeutics | Pre-Series A | 17M |
| 12/2021 | BioInno | Series A | - |
| 4/2018 | CMAB BioPharm | Series B | 0 |
| 10/2020 | Hinova Pharma | Series C | 0 |
| 12/2019 | EOC Pharma Group | Series C | 71M |
| 7/2021 | Adlai Nortye | Series D | 0 |
| 4/2022 | LTZ Therapeutics | Seed Round | 0 |
| 12/2021 | BioInno | Series A | - |
| 11/2021 | Jisi Yingda | Series B | - |
| 9/2021 | CytoLynx Therapeutics | Funding Round | 0 |
| 7/2021 | Adlai Nortye | Series D | 0 |
| 3/2021 | Gmax Biopharm | Series C | 0 |
| 10/2020 | Hinova Pharma | Series C | 0 |
| 8/2020 | Adlai Nortye | Series C | 0 |
| 6/2020 | Asieris Pharmaceuticals | Series C | 0 |
| 2/2020 | CANbridge Pharmaceuticals | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2008 | Series A | 1 | $6.3M |
Qiming Venture Partners Qiming Venture Partners Qiming Venture Partners Qiming Venture Partners |
3/2010 | Venture Round | 1 | $2M |
Qiming Venture Partners Qiming Venture Partners |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 10/2015 | DreamCIS | |
| 5/2014 | Frontage Laboratories |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
